New-onset atrial fibrillation predicts heart failure progression.

[1]  S. Liggett,et al.  Race, common genetic variation, and therapeutic response disparities in heart failure. , 2014, JACC. Heart failure.

[2]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[3]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[4]  C. O'connor,et al.  Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism. , 2013, JACC. Heart failure.

[5]  Richard B Devereux,et al.  Relationship of Sudden Cardiac Death to New-Onset Atrial Fibrillation in Hypertensive Patients With Left Ventricular Hypertrophy , 2013, Circulation. Arrhythmia and electrophysiology.

[6]  C. O'connor,et al.  Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation , 2013, European journal of heart failure.

[7]  Elsayed Z Soliman,et al.  Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. , 2013, JAMA internal medicine.

[8]  I. V. Van Gelder,et al.  The importance of whether atrial fibrillation or heart failure develops first , 2012, European journal of heart failure.

[9]  V. Roger,et al.  Atrial Fibrillation and Mortality in Heart Failure: A Community Study , 2011, Circulation. Heart failure.

[10]  L. Køber,et al.  Incidence of Atrial Fibrillation in Patients with either Heart Failure or Acute Myocardial Infarction and Left Ventricular Dysfunction: A Cohort Study , 2011, BMC cardiovascular disorders.

[11]  C. O'connor,et al.  Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST]). , 2010, American heart journal.

[12]  W. Stevenson,et al.  Atrial Fibrillation in Congestive Heart Failure , 2010, Cardiology in review.

[13]  J. McMurray,et al.  The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature‐based meta‐analysis , 2009, European journal of heart failure.

[14]  W. Aronow,et al.  A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. , 2009, European heart journal.

[15]  S. Liggett,et al.  Determination of Hospitalization Type by Investigator Case Report Form or Adjudication Committee in a Large Heart Failure Clinical Trial (BEST) , 2008 .

[16]  L. Køber,et al.  Atrial fibrillation, ischaemic heart disease, and the risk of death in patients with heart failure. , 2006, European heart journal.

[17]  D. J. Veldhuisen,et al.  Presence and development of atrial fibrillation in chronic heart failure , 2006, European journal of heart failure.

[18]  A. Moss,et al.  Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. , 2006, Heart rhythm.

[19]  Douglas L Mann,et al.  Mechanisms and models in heart failure: the biomechanical model and beyond. , 2005, Circulation.

[20]  M. Domanski,et al.  Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the &bgr;-Blocker Evaluation of Survival Trial , 2004, Circulation.

[21]  A. John Camm,et al.  Atrial fibrillation and heart failure: natural history and pharmacological treatment. , 2004, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[22]  G. L’italien,et al.  The expanding national burden of heart failure in the United States: the influence of heart failure in women. , 2004, American heart journal.

[23]  M. Domanski,et al.  The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. , 2003, Journal of the American College of Cardiology.

[24]  J. Murabito,et al.  Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality The Framingham Heart Study , 2003, Circulation.

[25]  M. Domanski,et al.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001, The New England journal of medicine.

[26]  T. R. I. Nvestigators A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE , 2001 .

[27]  M A Waclawiw,et al.  Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. , 1998, Journal of the American College of Cardiology.

[28]  L. Tavazzi,et al.  Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. , 1998, Journal of the American College of Cardiology.

[29]  R. Coleman,et al.  Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. , 1986, The American journal of cardiology.